Citius Pharmaceuticals (CTXR) Total Current Liabilities (2011 - 2026)

Citius Pharmaceuticals (CTXR) has reported Total Current Liabilities for 16 consecutive years, with $51.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities changed 0.37% year-over-year to $51.6 million; the trailing twelve-month figure through Jun 2026 stood at $51.6 million (changed 0.37% YoY), and the FY2025 full-year result was $44.9 million, up 25.41% from the prior year.
• Total Current Liabilities retreated to $51.6 million in Q2 2026 per CTXR's latest filing, from $55.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $55.0 million in Q1 2026 and bottomed at $4.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $23.4 million across 5 years, with a median of $6.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities sank 38.2% in 2022, then soared 1148.59% in 2025.
• Over 5 years, Total Current Liabilities stood at $4.5 million in 2022, then rose by 22.96% to $5.6 million in 2023, then surged by 703.14% to $44.8 million in 2024, then decreased by 14.73% to $38.2 million in 2025, then soared by 35.18% to $51.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $51.6 million, $55.0 million, and $38.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.